ATTO
HOLD / NEUTRALNeutralComposite
46.80
Technical
49.70
Fundamental
44.90
Rank
—
Price
21.40
Hurst
—
As of
Sep 1, 2026
Daily
Attovia Therapeutics, Inc.
HealthcareBiotechnologyAttovia Therapeutics is a clinical-stage biopharmaceutical firm developing treatments for immune-mediated diseases using its ATTOBODY platform, which creates biparatopic fusion proteins targeting multiple disease pathways. Its pipeline includes candidates for chronic itching conditions, atopic dermatitis and other inflammatory skin disorders, and inflammatory bowel disease, with mechanisms targeting cytokines and cellular adhesion molecules. The company was founded in 2022 and operates from San Carlos, California.
Market cap
$1.0B
P/E (trailing)
—
P/E (forward)
-9.55
PEG ratio
—
Dividend yield
—
Beta
—
52w range
16.15 – 28.00
Return on equity
—
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 22.25 (+1.6%) · range 18.06–25.55
Cycle position
74/ 100 cycle scoreAPPROACHING EXIT
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 13 · NOT READY · exit proximity 8
Conviction
24/ 100 · maturity 43%
VScore.223
Buildup.2639
EMA entry setup.3213
Fundamentals.1945
Volume profile
POC
20.53
Price vs POC
+8.3%
Overhead supply
29%
Runway
+0.8%
Value area 19.23–22.79 · 29% of 30d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.400 | Sep 1, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -5.83% | +5.58% | 5/20d |
| 40d | -5.83% | +5.58% | 5/40d |